Cessatech reports first subject dosed in bioavailability trial of lead product candidate
Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001. Primary aim of trial is to demonstrate drug-exposure following nasal administration of CT001 relative to the IV injection of approved drug counterpartsCessatech A/S announces that the 12-subject bioavailability trial (0204) has been initiated according to plan and will include adult healthy volunteers in a randomized three-treatment, three-period, single dose crossover design with a wash-out period of minimum 5 days and maximum 3 weeks. The study will investigate the absorption of CT001 nasal